1. ESMO: J&J's Rybrevant combo beats Tagrisso on lung cancer progression. Should AZ worry?
Johnson & Johnson’s Rybrevant—combined with its Yuhan-partnered lazertinib—went head-to-head with AstraZeneca’s Tagrisso in the closely watched MARIPOSA trial. J&J’s regimen was able to reduce the risk of disease progression or death by 30% versus Tagrisso in patients with newly diagnosed, EGFR-mutant non-small cell lung cancer. The company will present the full results at the European Society for Medical Oncology 2023 congress.
2. Elevar commits $600M-plus to take Hengrui's liver cancer cocktail to market in US and beyond
Elevar Therapeutics will pay Hengrui Pharmaceuticals up to $600 million in milestones—plus potential royalties—to market the duo’s combination of VEGFR therapy rivoceranib and PD-1 inhibitor camrelizumab worldwide. The deal, which does not cover the greater China region and Korea, could eventually reach a value of $1 billion over 10 years. An FDA decision on the liver cancer combo is slated for May 2024.
Seagen and Astellas’ Padcev—combined with Merck’s star Keytruda—made waves in a phase 3 bladder cancer trial. In a trial of 886 patients, the combination reduced the risk of death by 53% over chemo and similarly cut the risk of disease progression or death by 55%.
Takeda’s stem cell therapy Alofisel missed the mark in a phase 3 trial testing the treatment in complex perianal fistulas, a debilitating complication of Crohn’s disease. While the company didn’t report the full data, it divulged that Alofisel didn’t meet its primary endpoint of combined remission at 24 weeks. Takeda is continuing to “assess the financial impacts” of the results.
6. Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee
Takeda will fork over 130 million euros (about $137 million) to resolve a tax assessment from the Irish Revenue Commission. The fee dates back to 2018, when Irish authorities charged Shire 398 million euros in relation to AbbVie’s abandoned takeover bid in 2014. When Takeda bought Shire for $62 billion in 2019, it assumed responsibility for the charge and had been challenging it until the recent settlement.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.